Loading...
Thumbnail Image
Publication

Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation

Randall, Adam
Hull, Ilana
Martin, Stephen A
Embargo Expiration Date
Abstract

Buprenorphine-naloxone (BUP-NX) is a lifesaving treatment for opioid use disorder. The increasing use of illicitly manufactured fentanyl, however, has made initiating BUP-NX more likely to precipitate withdrawal-an experience that deters treatment and causes return to use. If BUP-NX cannot be successfully started, it cannot work. We describe the case of a patient who was able to transition to a therapeutic dose of BUP-NX less than 3 hours after his last illicitly manufactured fentanyl use by choosing to self-administer intranasal naloxone. After the naloxone, the transition took 31 minutes, including 14 minutes of expected moderately severe withdrawal. He remains in care with BUP-NX and would recommend this transition approach to others.

Source

Randall A, Hull I, Martin SA. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation. J Addict Med. 2023 Mar-Apr 01;17(2):237-240. doi: 10.1097/ADM.0000000000001073. Epub 2022 Sep 22. PMID: 36149001; PMCID: PMC10022654.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1097/ADM.0000000000001073
PubMed ID
36149001
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine. This is an open access article dis- tributed under the terms of the Creative Commons Attribution-Non Commercial- No Derivatives License 4.0 (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.Attribution-NonCommercial-NoDerivatives 4.0 International